Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyang Pharma Univ. CDK9 compound LB-1
- Development stage
- Preclinical
- Lead developer
- Shenyang Pharmaceutical University
01
Overview
Shenyang Pharma Univ. CDK9 compound LB-1: sourced facts only. name: "Moreover, compared with AZD5438, LB-1 demonstrated highly selective CDK9 inhibitory activity, with an IC50 value of 9.22 nM." [PMID:40162202]; target: "Moreover, compared with AZD5438, LB-1 demonstrated highly selective CDK9 inhibitory activity, with an IC50 value of 9.22 nM." [PMID:40162202]; developer: "Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University Shenyang 110016 China [email protected]." [PMID:40162202]; stage: "Compound LB-1 exhibited potent CDK9 inhibition and induced apoptosis in the HCT116 cell line." [PMID:40162202]
02
Targets
CDK9 (Cyclin-dependent kinase 9)
Beyond the preview
Go deeper on Shenyang Pharma Univ. CDK9 compound LB-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Pharma Univ. CDK9 compound LB-1.